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The striatum and its ventral extension the nucleus accumbens
(NAcc) are the main inputs structure of the basal ganglia cir-
cuit (Figure 1). While the striatum appears to be essential for the
selection and initiation of actions and for the learning of habits
and skills, the NAcc seems to be more involved in motivation and
reward. Interestingly, dysfunctional plasticity of these structures
has been associated with prominent neurological and psychi-
atric disorders such as Parkinson’s disease, obsessive-compulsive
disorder, Tourette’s syndrome, and drug addiction.
The aims of this Special Topic was to propose a series of
reviews covering our recent understanding on striatal signaling
pathways, which are activated by a variety of therapeutic agents
or drugs of abuse in physiological and pathological context. The
17 articles provide a deep overview of our current knowledge and
highlight how recent advances in cell-type specific technologies,
including fluorescent reporter mice, conditional knockout, and
viral-mediated gene transfer allow to untangle the complexity of
studying signal transduction in the brain in vivo. The content of
each of these articles is briefly summarized below.
The first article, by Nishi et al. (2011) summarizes some
of the mechanisms involved in the modulation of dopamine
D1R signaling. The authors review both the canonical and non-
canonical D1R signaling cascade that coupled to Gαolf/adenylyl
cyclase/PKA signaling and to Gq/phospholipase C or Src fam-
ily kinase, respectively. They also extensively discuss the role
played by Phosphodiesterases (PDEs) in the control of striatal
signaling. In the second article, Hervé (2011) reviews the criti-
cal role of the highly specialized G-protein subunit heterotrimer
containing Gαolf/β2/γ7 that couples D1R and A2aR to adeny-
lyl cyclase 5. The physiological consequences of the alterations
of Gαolf levels and/or activity are also extensively discussed.
The third article by Perreault et al. (2011) reviews the current
knowledge on D1R-D2R heteromers. Although, it is commonly
accepted that D1R and D2R are preferentially expressed in stri-
atonigral and striatopallidal MSNs, respectively, the authors put
forward the hypothesis that MSNs co-expressing both receptors
display unique signaling properties supporting the existence of
a “novel third pathway”. Ferré et al. (2011) focus on the role
of the different subpopulation of striatal adenosine A2aR. Post-
synaptically, A2aR are localized in striatopallidal MSNs where
they form heteromers with dopamine D2R, cannabinoid CB1R,
andmGluR5R. The authors also highlight how presynaptic A2aR-
A1R heteromers can impact on striatal signaling. After a brief
overview of the major G-protein-coupled receptors (GPCRs) and
their downstream effectors, Xie and Martemyanov (2011) discuss
the progress made in understanding the roles of RGS proteins in
controlling striatal G-protein signaling. A particular attention has
been paid on the role of the striatal-enriched RGS9-2 protein on
dopamine and opioid signaling. The sixth article by Del’Guidice
et al. (2011) deals with the role of β-arrestin 2 on the regulation
of dopamine receptor desensitization as well as the involvement
of this scaffoling protein in the control of the Akt/GSK3 signaling
pathways. Potential molecular targets of β-arrestin 2/Akt/GSK3
signaling are also reviewed. After an outline of the current knowl-
edge of the signaling cascades that target the nucleus, Matamales
and Girault (2011) describe how through the regulation of pro-
tein kinases, phosphatases, and transport through the nuclear
pore, a signal initiated at the plasmamembrane is amplified in the
cytosol and then relayed to the nucleus. Identified mechanisms
involved in transcription regulation and chromatin re-modeling
in MSNs are also discussed. In the eighth article Walaas et al.
(2011) provide a comprehensive review on the regulation and
roles of the three major subclasses of serine/threonine protein
phosphatases, PP1, PP2B, and PP2A. Their direct or indirect
regulation by the striatum-enriched phosphoproteins DARPP32,
RCS, and ARPP-16 is extensively discussed. The ninth article
by Fitzpatrick and Lombroso (2011) also deals with the role of
protein phosphatases focusing more specifically on the striatal-
enriched protein tyrosine phosphatase (STEP). The structure and
the regulation of STEP phosphorylation are described, as are
the functional consequences of STEP dysfunctions in various
neurological and neuropsychiatric disorders.
The dysregulation of striatal signaling induced by the drugs
of abuse leads to an abnormal neuronal plasticity that under
normal circumstances serves to shape appropriate reward-related
behaviors. After a rapid update on the role played by dopamine
receptors in drug addiction, Philibin et al. (2011) perform an
in-depth review of intracellular signaling cascades, involving spe-
cific kinases and phosphatases affected by cAMP and Ca2+ that
modulate neuroplasticity to affect behavioral outcome. Particular
emphasis is placed on PKA, cdk5, ERK, CamKII, and PKC.
Glutamate receptors cooperate closely with dopamine to regulate
striatal signaling. In the article of Mao et al. (2011) several major
types of post-translational modifications of glutamate receptors,
including phosphorylation, palmitoylation, ubiquitination, and
sumoylation are discussed. The impact of such modifications
on striatal signaling and drug-induced neuronal plasticity is also
addressed. The article by Lobo and Nestler (2011) discuss exten-
sively how recent advances in cell-type-specific technologies have
advanced the field toward a more comprehensive understanding
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FIGURE 1 | Single confocal image showing DARPP-32
immunoreactivity (red) and EGFP fluorescence (cyan) in Drd2-EGFP
BAC transgenic mice. DARPP-32 allows the identification of all striatal
medium-sized spiny neurons (MSNs) while EGFP labels striatopallidal
MSNs and large aspiny cholinergic interneurons. Picture by E. Valjent.
of the distinct molecular and functional contributions of stria-
tonigral and striatopallidal MSNs in drug addiction. The article
by Durieux et al. (2011) also deals with the development of new
models and techniques allowing the selective targeting of striatal
MSNs and interneurons. Although these approaches represent
invaluable tools, the authors point out the need of an extensive
characterization to avoid overstated conclusions.
Altered striatal signaling in neurological disease has been
also covered in this Special Issue. Thus, the contribution of
Murer and Moratalla (2011) deals with the abnormal striatal
signaling observed in response to L-DOPA in the context of
Parkinson’s disease. Transcriptional and translational molecu-
lar mechanisms that may translate enhanced D1 signaling into
dyskinetic movements are discussed, as are the role of D2/D3R-
mediated signaling. Bonito-Oliva et al. (2011) review the key
role played by DARPP-32 in the actions of antiparkisonian
and antipsychotic drugs. The emerging picture indicating that
L-DOPA-induced dyskinesia and extrapyramidal syndrome are
linked to abnormal cAMP signaling in striatonigral and stri-
atopallidal MSNs is also discussed. After a brief overview of the
clinical aspects, genetics, and neuropathology, Roze et al. (2011)
summarize our current knowledge on the molecular mechanisms
underlying Huntington’s disease. Changes in axonal transport
and synaptic dysfunction have been discussed, as are transcrip-
tional dysregulation observed at the striatal level. Finally, the last
article by Crittenden and Graybiel (2011) provides a compre-
hensive review on the current state of knowledge of the details
of striosome-matrix compartimentalization on the striatum and
alterations in various disease states.
I am grateful for the enthusiasm and willingness shown by so
many colleagues in the field of striatal signaling to contribute an
article in this Special Issue. Some of the contributors also served
as expert reviewers for articles. In addition, I would like to thank
external reviewers for their valuable criticisms and suggestions
that contributed to the success of this Special Issue.
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